Table 1.
Baseline characteristics
| Conventional dosing n = 30 | Genotype‐guided dosing n = 30 | P value | |
|---|---|---|---|
| Age, mean ± SD | 12.5 ± 3.6 | 12.0 ± 3.7 | 0.66 |
| Gender, n (%) | |||
| Female | 17 (57) | 17 (57) | 1.00 |
| Race, n (%) | |||
| White | 27 (90) | 20 (67) | 0.10 |
| African American | 1 (3) | 3 (10) | |
| Other | 2 (7) | 7 (23) | |
| Ethnicity, n (%) | |||
| Hispanic/Latino | 6 (20) | 7 (25) | 0.64 |
| Body composition, mean ± SD | |||
| Weight (kg) | 50.5 ± 20 | 49.8 ± 20 | 0.90 |
| BMI | 21.1 ± 4.8 | 20.5 ± 4.8 | 0.61 |
| BMI Z score | 0.6 ± 1.1 | 0.3 ± 1.7 | 0.46 |
| Medical information, n (%) | |||
| Prior GER diagnosis | 8 (27) | 10 (33) | 0.78 |
| Asthma | 5 (17) | 6 (20) | 0.79 |
| Bronchitis | 6 (20) | 4 (13) | 0.49 |
| Sinusitis | 7 (23) | 3 (10) | 0.30 |
| Pneumonia | 3 (10) | 1 (3) | 0.61 |
| Hay fever | 3(10) | 3 (10) | 1.00 |
| Seasonal allergies | 5 (17) | 3 (10) | 0.45 |
| Frequency of heartburn symptoms, n (%) | |||
| Daily | 8 (27) | 10 (33) | 0.80 |
| 2–6x per week | 15 (50) | 11 (37) | |
| 1–4x per month | 3 (10) | 5 (17) | |
| Never | 4 (13) | 4 (13) | |
| Medication use, n (%) | |||
| OTC antacida | 13 (43) | 12 (40) | 0.58 |
| H2RA | 7 (23) | 13 (47) | 0.09 |
| PPI | 8 (27) | 4 (13) | 0.20 |
| OME, mean ± SD | 19 ± 4 | 30 ± 20 | 0.34 |
| Omeprazole | 5 (62) | 3 (75) | 0.79 |
| Pantoprazole | 1 (12) | 0 (0) | |
| Lansoprazole | 1 (12) | 0 (0) | |
| Esomeprazole | 0 (0) | 1 (25) | |
| Unknown | 1 (12) | 0 (0) | |
BMI, body mass index; GER, gastroesophageal reflux; H2RA, histamine receptor antagonist; OTC, over‐the‐counter; OME, omeprazole equivalent dose in milligrams; PPI, proton pump inhibitor.
Examples of OTC include: sodium bicarbonate, magnesium hydroxide, aluminum hydroxide, calcium carbonate, and bismuth subsalicylate.